BridgeBio Pharma enters the final week of September with a curious split: the stock has given back 15% over the past month yet recovered nearly 4% on Tuesday, while two of its largest activist investors have been quietly reducing positions — a tension worth unpacking before the October 30 earnings date.
The short interest picture is notable in scale but moving in the right direction for bulls. At 11.2% of free float, the short base remains elevated for a biotech with genuine commercial momentum. Yet bears have been covering, not adding — short interest has dropped roughly 5% over the past month, from around 23.3 million shares in early September to 21.7 million. The borrow market does nothing to incentivise fresh shorts: cost to borrow is just 0.57%, well within easy-loan territory, and availability is an exceptionally loose 1,676% — meaning roughly 17 shares remain available for every one already borrowed. With 185 million shares accessible in the lending pool, there is no mechanical squeeze pressure here. The ORTEX short score has eased from 58.8 on September 9 to 56.6 this week, confirming the modest directional shift away from short-side pressure.
Options positioning has shifted, and not in the bullish direction. The put/call ratio is running well above its recent baseline — at 0.27, it is nearly 1.7 standard deviations above the 20-day mean of 0.19. That sounds modest in absolute terms, but for BBIO, which has spent most of the past six weeks with a PCR below 0.16, the jump is material. The change coincides with the stock's sharp September slide from above $80. Options traders appear to be hedging a position rather than expressing a directional view — the ratio remains far below the 52-week high of 1.17 — but the shift is worth noting heading into an earnings event where the last two prints produced negative five-day returns.
The Street remains overwhelmingly constructive. Mizuho raised its target to $110 from $96 on September 1, with JP Morgan having lifted to $111 from $100 earlier in August after Q2 results. The consensus mean target sits near $109 — implying roughly 57% upside from the current $69.23 close. Most of the August post-earnings revisions were upward, with only Morgan Stanley trimming modestly (to $97 from $98 on a maintained Overweight). The bull case centres on Attruby's commercial ramp in transthyretin amyloid cardiomyopathy, with data recently presented at the ESPE Meeting reinforcing the programme's profile. Bears point to pipeline concentration risk — BBIO remains dependent on a handful of programmes, and competition in the ATTR-CM space is real. The forward EPS factor scores reflect the commercial progress, with the 12-month forward earnings trajectory ranking in the 87th percentile. Near-term momentum tells a different story: both 30-day and 90-day EPS momentum rank in the bottom fifth of the universe, at the 7th and 16th percentiles respectively. The business is building; the near-term tape is lagging.
The activist register carries two Schedule 13D filers, both of which have been reducing exposure. Viking Global Investors trimmed from 6.1% to 5.0% as last disclosed in July, while KKR cut its stake from 7.0% to 4.7% as of August — a larger move, crossing back below the 5% reporting threshold. Neither exit has been disorderly, and both remain sizeable holders in absolute terms. The institutional roster still reads like a conviction book: Janus Henderson at 7.2%, Farallon at 5.5%, and Wellington adding nearly 2.8 million shares in the period. CEO Neil Kumar sold approximately $690,000 worth of shares on September 17 and a larger cluster in August, all under a pre-arranged 10b5-1 plan — scheduled sales, not a discretionary call, and his disclosed beneficial ownership remains above 2.5% of the company. The caveat on the activist stakes bears repeating: 13D/G disclosures are event-driven around the 5% threshold, and a holder who drops below 5% may not file again.
Within the peer group, VKTX surged 35.7% on the day and 36.4% on the week — the kind of binary catalytic move that can shift sentiment across the mid-cap biotech cohort. CTMX gained 6.5% Tuesday and IMNM added 2.7%, suggesting a broadly positive day for clinical-stage names. Against that backdrop, BBIO's 3.98% Tuesday gain looks relatively modest for a name with a 57% implied upside from consensus — the month-long slide appears to have left some scepticism to work through before October 30.
The next focal point is the Q3 earnings call on October 30: the key question is whether Attruby's commercial trajectory can close the gap between the $109 consensus target and where the stock is actually trading.
See the live data behind this article on ORTEX.
Open BBIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
